DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NHL and CLL for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.

DRG Epidemiology’s NHL and CLL forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with NHL and CLL per year?
  • How will improvements in survival change the number of people living with a diagnosis of NHL and CLL?
  • Of all people diagnosed with NHL and CLL, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NHL and CLL over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient-flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology forecasts the following NHL subpopulations:

  • Diagnosed incident cases of NHL by histology (follicular lymphoma [FL], diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], CLL/small lymphocytic lymphoma [SLL], T-cell/natural killer [NK]-cell).
  • Transformed incident cases (FL to DLBCL and CLL to DLBCL).
  • Diagnosed prevalent cases of NHL by histology (FL, DLBCL, MCL, CLL/SLL, T-cell/NK-cell).
  • Drug-treatable populations (FL, DLBCL, MCL, CLL/SLL, T-cell/NK-cell).
  • Drug-treated status (FL, DLBCL, MCL, CLL/SLL).

Note: Coverage may vary by country.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Emerging Markets

Author(s): Stephanie Niquita; Nishant Kumar

Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.


Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030: Diagn...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Geographic Focus: China - China In-Depth | China

Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate...

View Details